



Market Announcement

8 October 2019

Zelda Therapeutics Limited (ASX: ZLD) – Trading Halt

Description

The securities of Zelda Therapeutics Limited ('ZLD') will be placed in trading halt at the request of ZLD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 10 October 2019 or when the announcement is released to the market.

Issued by

Sandra Wutete

Senior Adviser, Listings Compliance (Perth)



8 October 2019

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000
Attention: Anjuli Sinniah
By email only: anjuli.sinniah@asx.com.au

Dear Madam,

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelda Therapeutics Limited ('the Company', ASX: **ZLD**) requests the granting of a trading halt in ZLD's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to a material control transaction with a US based healthcare group;
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Thursday, 10 October 2019 or the making of an announcement in respect to a material control transaction with a US based healthcare group; and
3. ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial program** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research program** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA's EU- GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.